HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. They currently have a $54.00 price target on the stock. Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a buy rating and set […]